Loading
An oncolytic virus blows up tumour cells and inflames the tumour; PD-1 blockade then exploits the inflammation.
This combination pairs Oncolytic viruses with Immune checkpoint inhibitors in Melanoma: the virus blows up tumour cells and inflames the tumour, and PD-1 blockade then exploits the inflammation. The mechanism is that viral lysis releases antigens and virus-encoded GM-CSF, and the resulting interferon response upregulates PD-L1, which nivolumab blocks. RP1 (Vusolimogene oderparepvec) plus Nivolumab received accelerated approval in August 2026 for PD-1-refractory melanoma on the IGNYTE study, which produced responses including in uninjected lesions. By contrast, Talimogene laherparepvec plus pembrolizumab did not improve outcomes in the first-line setting (MASTERKEY-265), showing that the treatment setting matters.
Shares Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma, Talimogene laherparepvec, Oncolytic viruses, Melanoma.
Shares Vusolimogene oderparepvec, Oncolytic viruses, Nivolumab, Melanoma.
Shares Talimogene laherparepvec, Oncolytic viruses, Melanoma.
Shares Vusolimogene oderparepvec, Talimogene laherparepvec, Oncolytic viruses, Melanoma.
Shares Vusolimogene oderparepvec, Talimogene laherparepvec, Oncolytic viruses, Melanoma.
Shares Talimogene laherparepvec, Melanoma.
Shares Oncolytic viruses, Melanoma.